Huntingtin Protein And Striatal Neuron Degeneration is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The HTT gene (Huntingtin) encodes huntingtin protein (HTT), a large multi-domain protein of approximately 3,144 amino acids. Mutations in HTT cause Huntington's disease (HD), an autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances [1][2]. The disease is caused by an unstable CAG trinucleotide repeat expansion in the first exon of the HTT gene, resulting in an expanded polyglutamine (polyQ) tract in the huntingtin protein. This mutation leads to a toxic gain-of-function that disrupts multiple cellular processes, ultimately causing selective degeneration of striatal medium spiny neurons (MSNs) and cortical pyramidal neurons. [1]
Huntington's disease affects approximately 5-10 per 100,000 people worldwide, with onset typically occurring in mid-adulthood (30-50 years), although juvenile-onset forms exist with longer repeat expansions. The selective vulnerability of striatal MSNs, which constitute approximately 95% of striatal neurons and are the most severely affected in HD, has made this cell type a focus for understanding disease mechanisms and developing therapies [1]. [2]
Wild-type huntingtin is an essential protein with multiple cellular functions: [3]
Development and embryogenesis require huntingtin for: [4]
Vesicle trafficking and axonal transport functions include: [5]
Gene transcription regulation involves: [6]
Synaptic function maintenance through: [7]
Neurotrophic support via: [8]
The expanded polyglutamine tract confers toxic properties to mutant huntingtin: [9]
Polyglutamine expansion characteristics: [10]
Toxic gain-of-function mechanisms: [11]
Protein aggregation involves: [12]
Transcriptional dysregulation through: [13]
Striatal medium spiny neurons exhibit particular vulnerability to mHTT toxicity: [14]
MSN subtypes include: [15]
Vulnerability factors specific to MSNs: [16]
Neuroanatomical considerations: [17]
Selective MSN loss in HD involves: [18]
Cortical neuron degeneration features: [19]
Early axonal dysfunction precedes cell death: [20]
Multiple interconnected mechanisms drive neurodegeneration in HD:
mHTT aggregation pathology:
BDNF transport defects:
Excitotoxicity mechanisms:
Mitochondrial dysfunction includes:
Autophagy impairment involves:
Transcriptional repression through:
Synaptic dysfunction includes:
Antisense oligonucleotides (ASOs):
RNA interference (RNAi) approaches:
CRISPR-Cas9 gene editing:
Mitochondrial function enhancement:
Excitotoxicity reduction:
Autophagy induction:
Trophic factor support:
](/mechanisms/bdnf-transport-defects
--excitotoxicity-in-hd
--huntingtin-protein
--polyglutamine-expansion
--basal-ganglia-circuitry)## Background
The study of Huntingtin Protein And Striatal Neuron Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Ross & Tabrizi, HD pathogenesis (2011)](https://doi.org/10.1016/S1474-4422(11). 2011. ↩︎
Gunawardena et al. Axonal transport defects (2003). 2003. ↩︎
Usdin et al. Synaptic dysfunction in HD (2019). 2019. ↩︎
Zuccato et al. BDNF in HD (2001). 2001. ↩︎
Cattaneo et al. Normal and mutant huntingtin (2005). 2005. ↩︎
Sapp et al. Huntingtin aggregation in HD brain (2005). 2005. ↩︎
Ferrante et al. [Selective vulnerability of MSNs (1991)](https://doi.org/10.1016/0306-4522(91). 1991. ↩︎
Graybiel, Basal ganglia-thalamocortical circuits (2000). 2000. ↩︎
Rosas et al. Cortical thinning in HD (2008). 2008. ↩︎
Baekelandt et al. [BDNF gene therapy in HD (2002)](https://doi.org/10.1016/S0306-4522(02). 2002. ↩︎
Shin et al. Excitotoxicity in HD (2005). 2005. ↩︎
Browne et al. Mitochondrial dysfunction in HD (1999). 1999. ↩︎
Martinez-Vicente et al. Autophagy in HD (2010). 2010. ↩︎
Tabrizi et al. ASO therapy for HD (2019). 2019. ↩︎
Drouet et al. RNAi therapy in HD (2009). 2009. ↩︎
Shin et al. CRISPR editing of HD (2016). 2016. ↩︎
Hersch & Ferrante, Neuroprotective therapies in HD (2004). 2004. ↩︎
Giralt et al. PDE10A inhibition in HD (2011). 2011. ↩︎